Genmab — November 2018

[Nickstar]

Er glad for du har fået HH ind i folden, Helge.

[Helge_LarsenPI-redaktør]

Vi har arbejdet sammen før. Nu fik vi muligheden igen.

[Helge_LarsenPI-redaktør]

God morgen.

[bibob]

God morgen.

[polle1]

God morgen og god dag

[E_L]

NEJM : Daratumumab for Delayed Red-Cell Engraftment after Allogeneic Transplantation https://www.nejm.org/doi/full/10.1056/NEJMoa1807438

[E_L]

"Within 1 week after the initiation of treatment with daratumumab, he no longer required transfusions." ………..wtf

[E_L]

New trial: Evaluation of the Safety and Efficacy of the Association of Ibrutinib and Daratumumab in Relapsed/Refractory Chronic Lymphocytic Leukemia With p53 Dysfunction (IDA53) https://clinicaltrials.gov/ct2/show/NCT03734198

[Parasitism]

God morgen

[E_L]

and if you are on twitter , have a look at Natalie Callander‏ @nsc_natalie where she talks about a new trial in preparation for Smoldering , Dara + Len/dex, which she hopes to start Feb19

[E_L]

https://twitter.com/mtmdphd/status/1060287065903034368

[E_L]

God morgen indeed

[E_L]

The SC combo trial adds an extra arm, (D-Kd)
https://clinicaltrials.gov/ct2/history/NCT03412565?A=12&B=13&C=merged

[gentogen]

Thanks El. Og lidt apropos: WM cell lines treated with the ibrutinib + Dara combination, showed significantly more cell death through ADCC, CDC, ADCP and apoptosis relative to single‐agent Dara or ibrutinib. In summary, we are the first to report the in vitro and in vivo anti‐WM activity of Dara. Furthermore, we show a close connection between BCR and CD38 signalling, which can be co‐targeted with ibrutinib + Dara to induce marked WM cell death.(British Journal of Haematology 183(2) · August18

[polle1]

"Pop"

[OHW]

Fin kursudvikling

[Legolas23]

THX for link

[StockBull]

Ser ud til shorts er øget med 0.4% i.f.t September som var 3.27% 30 sept. mod nu 3.65% 31 okt.

[Parasitism]

Det passer vel også meget godt - var det ikke ca. 1 nov. at AB begyndte at ligge som største nettokøber mange af dagene?

[Bulder]

Despite the addition of a new arm, the sc combo trial is shortened down with almost a year. And at the same time the observation time frames are extended with a year. Any ideas how this fits together?